A2B530

A2 Biotherapeutics Inc. · Phase 1 active Biologic

At a glance

Generic name	A2B530
Also known as	Tmod CAR T-cell Therapy
Sponsor	A2 Biotherapeutics Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

A2B530 CI brief — competitive landscape report
A2B530 updates RSS · CI watch RSS
A2 Biotherapeutics Inc. portfolio CI